In an exclusive interview, Hua Su, Life Science and Healthcare practice leader and partner at Ernest &Young (EY) Parthenon, shares his recent comprehensive research on China's volume-based procurement (VBP) scheme for pharma and medtech products, as well as options for companies hit by spreading price-cutting schemes and pondering their next strategic moves in this key market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?